Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

July 8, 2020, 7:39 a.m. EDT

Merck, Eisai to put experimental cancer combination in new clinical trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Eisai Co. Ltd. (4523)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK +1.04% gained 0.1% in premarket trading on Wednesday after it received a complete response letter from the Food and Drug Administration for an application to approve Keytruda in combination with Eisai Co. Ltd.'s /zigman2/quotes/203064480/delayed JP:4523 +2.74% Lenvima for a new indication. The regulator said the data that was provided in the application for the investigational combination therapy as a first-line treatment for unresectable hepatocellular carcinoma didn't demonstrate "a meaningful advantage" over existing therapies. The companies plan to conduct a new Phase 3 trial, which is already fully enrolled. They are also testing the Keytruda/Lenvima combination in 17 other clinical trials. Merck's stock has declined 13.4% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.20% is down 2.6%.

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 83.54
+0.86 +1.04%
Volume: 7.11M
Aug. 13, 2020 4:02p
P/E Ratio
20.34
Dividend Yield
2.92%
Market Cap
$209.12 billion
Rev. per Employee
$615,159
loading...
/zigman2/quotes/203064480/delayed
JP : Japan: Tokyo
¥ 9,671.00
+258.00 +2.74%
Volume: 1.06M
Aug. 14, 2020 3:00p
P/E Ratio
22.26
Dividend Yield
1.65%
Market Cap
¥2663.71 billion
Rev. per Employee
¥60.00M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,373.43
-6.92 -0.20%
Volume: 1.96B
Aug. 13, 2020 5:10p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.